Covid-19, EMA authorizes Johnson & Johnson single-dose vaccine
France authorizes Johnson & Johnson anticovid vaccine
Vaccini, Ema: "There are no indications of the link between AstraZeneca and thrombosis"
Vaccini Plan in final tightening: today a double confrontation with the Regions
EU-UK Vaccine Clash.
Michel: "London tell us how many doses you have exported"
Denmark temporarily suspends use of Astrazeneca vaccine
Share
March 12, 2021
Green light also from the Italian Medicines Agency (Aifa) to the anti-Covid vaccine of the Johnson & Johnson company for authorization for marketing and use within the National Health Service.
Yesterday, the J&J vaccine received approval from the European Medicines Agency Ema.
This is the fourth anti-Covid vaccine approved in Italy after those of Pfizer-BionTech, Moderna and AstraZeneca.
AIFA has authorized Johnson & Johnson's Janssen vaccine for the prevention of COVID-19 disease for individuals over the age of 18, as per EMA indication.
The vaccine will therefore be made available at the expense of the NHS.
The Technical-Scientific Commission (CTS) of the Agency met today and confirmed the EMA's assessment on the efficacy of the vaccine which in severe forms reaches up to 77% after 14 days from administration and 85% after 28 days from administration.
The data currently available, notes Aifa in a note, "showed that no decline in efficacy was noted in subjects over 65. The Janssen vaccine, the fourth approved, is added as another useful option with a significant benefit in fighting the pandemic ".